Abstract
Acute myeloid leukemia (AML) with mutated nucleophosmin (NPM1) has been defined as a distinct leukemia entity in the 2016 updated WHO classification of myeloid neoplasm. Our previous report showed that autophagic activity was elevated in NPM1-mutated AML, but the underlying molecular mechanisms remain elusive. Mount of study provides evidence that glycometabolic enzymes are implicated in the autophagic process. Pyruvate kinase isoenzyme M2 (PKM2), a key glycolytic enzyme, has been recently reported as a tumor supporter in leukemia. However, little is known about the roles of PKM2 in autophagic activity in NPM1-mutated AML. In this study, PKM2 highly expressed in NPM1-mutated AML, and partially, high levels of PKM2 were upregulated by PTBP1. Further experiments demonstrated that PKM2 mediated autophagic activation and increased the phosphorylation of key autophagy protein Beclin-1. Importantly, functional experiments demonstrated that PKM2 contributed to cell survival via autophagic activation. Ultimately, high PKM2 expression was associated with short overall and event-free survival time in NPM1-mutated AML patients. Our findings indicate for the first time that glycolytic enzyme PKM2 mediates autophagic activation and further contributes to cell survival in NPM1-mutated AML, suggesting that PKM2 may serve as a promising target for treatment of NPM1-mutated AML.
Introduction
Acute Myeloid Leukemia (AML) with mutations in the nucleophosmin (NPM1) gene represents a distinct clinical entity, accounting for up to 60% of "cytogenetically normal" AML cases. These cancer cells exhibit high levels of autophagy—a cellular "self-eating" process used to recycle damaged components and survive under stress. While this survival mechanism is well-documented, the exact molecular triggers in NPM1-mutated AML have remained elusive. This study investigates whether metabolic enzymes, specifically Pyruvate kinase isoenzyme M2 (PKM2), play a non-metabolic role in driving this autophagic activity and promoting leukemia cell survival.
Methods
The study employed a multi-disciplinary approach combining bioinformatics, molecular biology, and functional cell assays:
- Bioinformatics & Datasets: Analysis of the Oncomine and TCGA (The Cancer Genome Atlas) databases was performed to correlate PKM2 expression with AML subtypes and patient survival. Clinical validation was conducted using a cohort of 30 diagnostic bone marrow samples (14 NPM1-mutated, 16 unmutated).
- Cell Models: Experiments utilized NPM1-mutated (OCI-AML3) and non-mutated (THP-1, NB4, HL60, K562, KG1a) leukemia cell lines.
- Molecular Manipulation: Researchers used shRNA and siRNA to silence PKM2 and the splicing factor PTBP1, alongside plasmid transfection for overexpression studies.
- Biochemical & Functional Assays: Western blotting detected protein levels and specific phosphorylation events (p-Beclin-1 at Thr119). Cell viability and apoptosis were measured via CCK-8 and flow cytometry, respectively.
Results
PKM2 Overexpression in NPM1-Mutated AML
Initial bioinformatic screens and subsequent experimental validation confirmed that PKM2 levels are significantly higher in NPM1-mutated AML compared to non-mutated cases. This elevation was observed at both the mRNA and protein levels across various models.
As shown in the Western blot analysis, the NPM1-mutated OCI-AML3 line exhibits markedly higher PKM2 protein levels compared to other leukemia cell lines. This finding was corroborated by clinical data from patient bone marrow samples.
The PTBP1-PKM2-Beclin-1 Axis
The study found that the splicing factor PTBP1 regulates the high levels of the PKM2 isoform. Crucially, PKM2 acts as a protein kinase that phosphorylates Beclin-1 at the Thr119 residue. This phosphorylation event releases Beclin-1 from its inhibitor (Bcl-2), thereby initiating the autophagy cascade and providing a survival advantage to the leukemia cells.
Clinical Impact and Survival
High PKM2 expression was strongly associated with poor clinical outcomes. Patients with elevated PKM2 levels had significantly shorter Overall Survival (OS) and Event-Free Survival (EFS). The Hazard Ratio for OS was 2.810, indicating that high-PKM2 patients face nearly triple the risk of death compared to low-PKM2 patients. Functional rescue experiments using the autophagy activator Tat-Beclin-1 confirmed that PKM2's primary survival benefit is mediated through the autophagy pathway.
Conclusion
This research positions PKM2 as a vital "survival switch" in NPM1-mutated AML. By moonlighting as a kinase to activate autophagy, PKM2 helps cancer cells endure stress and resist apoptosis. These findings suggest that PKM2 is not only a significant prognostic marker but also a viable therapeutic target. Inhibiting the PKM2-mediated autophagic pathway could potentially sensitize leukemia cells to treatment and improve patient outcomes.
Summary updated